Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001638599-21-000270
Filing Date
2021-02-25
Accepted
2021-02-25 19:30:36
Documents
1
Period of Report
2021-02-23

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT doc3_7113.html 3  
1 PRIMARY DOCUMENT doc3_7113.xml 3 1518
  Complete submission text file 0001638599-21-000270.txt   2900
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014
Business Address
Brownstein Sara (Reporting) CIK: 0001844458 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 21682729